TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02989233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video
Study: NCT03001063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported Self-Management
Description: This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced treatment as usual
Description: Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
Study: NCT00035581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly I-poly C12U
Description: 200-400 mg IV infusions 2x/week for 24 weeks
Study: NCT00854711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: 80 PPM

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: inhaled nitric oxide
Description: 80 PPM
Study: NCT00505570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER® PFO Occluder Device
Description: PFO device closure
Study: NCT02307981

Intervention type: OTHER
Intervention: Training with vision teacher (visual rehabilitation)
Description: Individually adapted training With vision teacher
Study: NCT04012112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracolumbar brace (Flexpine brace)
Description: Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
Study: NCT02833389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: UTTR1147A matching placebo will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered SC.
Study: NCT02468284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Study: NCT00184522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflurax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Study: NCT01173692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
Study: NCT03565133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinine sham feeding quinine
Description: Oral sham feeding with quinine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinine sham feeding quinine
Description: Oral sham feeding with quinine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastric quinine
Description: A gastric capsule containing quinine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastric quinine
Description: A gastric capsule containing quinine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral sham feeding placebo
Description: Oral sham feeding with placebo (tap water)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral sham feeding placebo
Description: Oral sham feeding with placebo (tap water)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gastric placebo
Description: A gastric capsule containing placebo (cellulose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastric placebo
Description: A gastric capsule containing placebo (cellulose)
Study: NCT01162603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann and Perkins applanation tonometry
Description: IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann and Perkins applanation tonometry
Description: IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAFLUPROST 0.0015% EYEDROPS
Description: Tafluprost 0.0015% preservative-free ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LATANOPROST 0.005% EYEDROPS
Description: Latanoprost 0.005% preservative-added ophthalmic solution
Study: NCT03707171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
Study: NCT04513691

Intervention type: DIAGNOSTIC_TEST
Intervention: EOS Calculator
Description: Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
Study: NCT00422279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Replace Tapered Groovy
Description: Bone inductive implant placed in supralveoral position or extraction site
Study: NCT03707171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
Study: NCT03380884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude high-frequency vibration (LMHFV)
Description: Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
Study: NCT02141659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 Tablets.
Study: NCT03124225

Intervention type: DRUG
Intervention: DMARD

Intervention type: DRUG
Intervention: DMARD
Study: NCT03689218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maamta (Nutritious Food Supplement)
Description: Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wawamum (Lipid-Based Nutrient Supplement)
Description: Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
Study: NCT03618030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-063 oral capsules
Description: Daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsules
Description: Daily dose
Study: NCT01966731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
Study: NCT01887548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personality Traits Questionnaires
Description: Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personality Traits Questionnaires
Description: Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
Study: NCT00629590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaSite®
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
Study: NCT02141659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 Tablets.
Study: NCT02612870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ retro
Description: Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ peri
Description: Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
Study: NCT02612870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ retro 4-6
Description: Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sienna+ peri 4-6
Description: Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technetium 1
Description: Sentinel node marking with Technetium 1 day before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technetium 1
Description: Sentinel node marking with Technetium 1 day before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technetium 1
Description: Sentinel node marking with Technetium 1 day before surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technetium 1
Description: Sentinel node marking with Technetium 1 day before surgery
Study: NCT00728546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (Rifinah)
Description: The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
Study: NCT04249882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to active medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg twice a day
Study: NCT01228747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo tablets twice daily for 28 weeks
Study: NCT00697554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
Study: NCT01974466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal A
Description: controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR \<120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
Study: NCT03467178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Nucleic Acid Synthesis Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated Liposomal Doxorubicin
Description: Chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Chemotherapy medication
Study: NCT01974466

Intervention type: OTHER
Group type: OTHER
Intervention: Goal B
Description: controled fluid therapy：10\~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%
Study: NCT02857803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Intervention of 30 minutes, 3 times a week until reaching 12 sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil
Description: Intervention of 30 minutes, 3 times a week until reaching 12 sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
Study: NCT04002180

Intervention type: DRUG
Intervention: Vedolizumab (Genetical Recombination)
Description: Vedolizumab IV infusion
Study: NCT03337880

Intervention type: OTHER
Intervention: instrumental delivery
Description: the birth was assisted with an extractor.
Study: NCT03358329

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study: NCT02441205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval training
Description: all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (\~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
Study: NCT04448431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 10 or 20 mg/day, capsules, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine
Description: 50 mg/day capsules, orally
Study: NCT02088827

Intervention type: OTHER
Group type: OTHER
Intervention: Inactivity
Description: Subjects will remain inactive (lying on a bed) for 4 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Activity
Description: Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
Study: NCT00410865

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: INGN 201
Description: Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
Study: NCT03605030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel Lead Based Armboard
Description: Novel Lead Based Armboard

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Armboard
Description: Standard Armboard (without lead)
Study: NCT05993286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: At Week 0, the homework was to expose oneself to these sounds for 20 minutes a day, three days a week for three weeks.~At the Week 3 interview, the frequency and severity of the homework were adjusted based on the degree of improvement in the symptoms and the person's adherence to the instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound Therapy
Description: Participants were asked to listen to specifically modulated music for twenty minutes a day, three days a week, for the first three weeks. At the Week 3 assessment, if the patient reported no or little benefit in their misophonia symptoms, the instruction was modified (intensified) to listening to the same music for forty minutes a day, three days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.

Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducation
Description: A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: A psychoeducation session, prepared by the research team was delivered by the investigator to each patient at the study intake.
Study: NCT02646306

Intervention type: OTHER
Intervention: shoulder proprioceptive rehabilitation tool
Description: Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object.
Study: NCT04127656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid-Based Experimental Study Formula
Description: Amino Acid-Based Formula; fed ad libitum
Study: NCT03890471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative telephone call three days before surgery
Description: Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
Study: NCT01279902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus CHOP Immunochemotherapy
Description: The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
Study: NCT02462317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum A toxin
Description: botulinum toxin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: baclofen oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo toxin
Description: placebo injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toxin
Description: placebo injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo baclofen
Description: placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo baclofen
Description: placebo oral tablet
Study: NCT04572386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: light cure 3m single bond universal bond
Description: light -cure universal bond

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-cure universal bond (Palfique, Tokuyama, Japan)
Description: Self-cure universal bond with no light cure
Study: NCT01650974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNOT
Description: high flow nasal oxygen therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HFNOT
Description: high flow nasal oxygen therapy